---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-029123"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:50:01.289659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi Q2 net loss narrows to $8.1M; Haduvio achieves all endpoints in Phase 2b/3 prurigo nodularis trial

## Summary
- Q2 2022 net loss of $8.1M ($9.8M in Q2 2021); cash and securities $78.9M.
- Phase 2b/3 PRISM trial met primary endpoint (25% vs 14% WI-NRS 4-point reduction, p=0.0157) and all key secondary endpoints with statistical significance.
- Completed $55M private placement in April 2022 to fund clinical development of Haduvio.
- Topline data from Phase 2 CANAL chronic cough in IPF trial expected Q3 2022; FDA meeting scheduled for this quarter.

## SEC filing metadata
- accession: 0001564590-22-029123
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/0001564590-22-029123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/trvi-8k_20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-029123
- JSON: https://secwatch.observer/filing/0001564590-22-029123.json
- Plain text: https://secwatch.observer/filing/0001564590-22-029123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.